University of Pennsylvania HIV Clinical Trials Unit

宾夕法尼亚大学艾滋病毒临床试验单位

• 批准号: 10531194
• 负责人: Ian Frank
• 金额: $ 348.72万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-01 至 2027-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10531194
• 关键词: AIDS clinical trial group; AIDS prevention; Achievement; Adherence; Adolescent; Adult; Affect; Anti-Retroviral Agents; Behavior Therapy; Behavioral Research; Biology; Cardiovascular Diseases; Caring; Cells; Chronic Kidney Failure; Cities; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Unit; Communities; Conduct Clinical Trials; Consequences of HIV; Creativeness; Diagnosis; Drug Interactions; Dyslipidemias; Education; Effectiveness; Epidemic; Evaluation; Event; Faculty; Failure; Goals; HIV; HIV Infections; HIV prevention trial; HIV therapy; HIV vaccine; Hepatitis B Virus; Heterosexuals; Human immunodeficiency virus test; Immune response; Immunologics; Impairment; Incentives; Individual; Infection; Infection Control; Infrastructure; Injectable; Injecting drug user; International; Investigation; Leadership; Maintenance Therapy; Medical; Mentors; Monoclonal Antibodies; Mucous Membrane; Network Infrastructure; New Agents; Obesity; Oral; Outcome; Pathogenesis; Pennsylvania; Persons; Phenotype; Philadelphia; Physical Function; Population; Populations at Risk; Positioning Attribute; Prevention; Prevention strategy; Protocols documentation; Recovery; Research; Research Personnel; Resources; Risk; Risk Behaviors; Role; Science; Site; Structure; Support Groups; Testing; Therapeutic; Training; Treatment-related toxicity; Tuberculosis; Universities; Virus Activation; Vision; Work; antiretroviral therapy; career development; cis-female; clinical research site; clinical trial implementation; comorbidity; cost efficient; design; frailty; gender nonconforming; immune activation; immune function; implantable device; improved; latent HIV reservoir; medical schools; men who have sex with men; microbicide; neutralizing monoclonal antibodies; next generation; non-alcoholic fatty liver disease; novel; novel therapeutics; outbreak response; pre-exposure prophylaxis; prevent; preventive intervention; protocol development; purge; senescence; shared decision making; symposium; therapy design; transgender; treatment as prevention; treatment response; uptake; vaccine trial

ABSTRACT The University of Pennsylvania HIV Clinical Trials Unit (Penn HIV CTU) will build on its current infrastructure and further its commitment to provide scientific leadership to advance the science of HIV treatment and prevention within three HIV Clinical Research Networks, the Adult AIDS Clinical Trials Group (ACTG), the HIV Vaccine Trials Group (HVTN), and the HIV Prevention Trials Group (HPTN). The Penn HIV CTU features an integrated, efficient clinical trials organization with two clinical research sites (CRS), the Penn Therapeutics CRS, located on the Penn School of Medicine (PSOM) campus, that conducts ACTG trials; and the Penn Prevention CRS, separately located on the Penn campus, that conducts HVTN and HPTN supported trials. Penn investigators will continue to contribute to the scientific agendas of these Networks through participation on network committees and through submission of protocols and membership on protocol teams. In addition, the Penn HIV CTU will advance the research agendas of these Networks through the cost efficient implementation of clinical trials to improve the lives of people living with HIV infection and to prevent it among those at risk. The leadership of the Penn HIV CTU will mentor the next generation of clinical investigators by involving junior investigators at our site and elsewhere in activities at that promote their career development at both the Network and site level. Penn investigators will engage the local community affected by HIV when formulating priorities, we will inform the community about opportunities to participate in research, and educate the community about medical advances and opportunities to access them. Penn investigators have contributed to important advances in HIV therapeutics through the evaluation of strategies designed to control HIV replication in the absence of antiretrovirals and purge the latent reservoir, testing of novel agents to inhibit HIV replication, and by improving treatments and prevention of co-morbid conditions associated with HIV infection. Penn investigators have also contributed to advances in HIV prevention through the testing of HIV vaccines, long-acting antiretrovirals and monoclonal antibodies for pre-exposure prophylaxis, and through behavioral interventions designed to modify risk behaviors. It is our goal to make these advances available to all populations living with or at-risk for HIV infection, including men who have sex with men, cisgender women, transgender and gender non-conforming individuals, and persons who inject drugs. Given the resources, vision, and commitment of Penn investigators, the Penn HIV CTU is well positioned to support the initiative for Ending the HIV Epidemic in Philadelphia, a priority city, through achievements in HIV prevention, diagnosis, treatment.

摘要 宾夕法尼亚大学艾滋病毒临床试验单位(宾夕法尼亚大学艾滋病毒CTU)将在现有基础设施的基础上 并进一步承诺提供科学领导，以推动艾滋病毒治疗和治疗的科学 三个艾滋病毒临床研究网络内的预防，成人艾滋病临床试验小组(ACTG)，艾滋病毒 疫苗试验小组(HVTN)和艾滋病毒预防试验小组(HPTN)。宾夕法尼亚大学艾滋病毒CTU的特点是 集成、高效的临床试验组织，拥有两个临床研究站点(CRS)，即宾夕法尼亚治疗公司 CRS位于宾夕法尼亚医学院(PSOM)校园，负责进行ACTG试验；宾夕法尼亚大学 分别位于宾夕法尼亚大学校区的预防CRS，进行HVTN和HPTN支持的试验。 宾夕法尼亚大学的研究人员将继续通过参与为这些网络的科学议程做出贡献 在网络委员会上，通过提交协议和礼宾小组成员。此外, 宾夕法尼亚大学艾滋病毒CTU将通过成本效益推动这些网络的研究议程 实施临床试验，以改善艾滋病毒感染者的生活，并在 那些处于危险中的人。宾夕法尼亚大学艾滋病毒CTU的领导层将通过以下方式指导下一代临床研究人员 让我们现场和其他地方的初级调查人员参与促进他们职业发展的活动 网络级别和站点级别。宾夕法尼亚大学调查人员将在以下情况下与受艾滋病毒影响的当地社区接触 制定优先事项，我们将向社会公布参与研究和教育的机会 关于医学进步和获得这些进步的机会的社区。宾夕法尼亚大学的调查人员已经 通过评估旨在控制艾滋病毒的战略，促进艾滋病毒治疗方面的重要进展 在没有抗逆转录病毒药物和清除潜伏库的情况下，检测艾滋病毒复制的新药物以抑制 艾滋病毒复制，以及改善治疗和预防与艾滋病毒有关的并存疾病 感染。宾夕法尼亚大学的研究人员还通过检测艾滋病毒，为艾滋病毒预防方面的进步做出了贡献 疫苗、长效抗逆转录病毒药物和单抗，用于暴露前预防，并通过 旨在改变危险行为的行为干预。我们的目标是将这些进步提供给 所有感染艾滋病毒或有感染艾滋病毒风险的人群，包括男男性行为者、顺性女性、 变性人和性别不符的人，以及注射毒品的人。如果有足够的资源， 宾夕法尼亚大学调查人员的远见和承诺，宾夕法尼亚大学艾滋病毒CTU处于有利地位，支持这一倡议 通过在艾滋病毒预防、诊断和治疗方面的成就，结束重点城市费城的艾滋病毒流行。 治疗。